Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-402

I had a look back on HC when the announcement was made and found no discussions particular for this control group. They also say this in the announcement:

"The results of the comparative analysis between Mesoblast’s open-label Phase 3 study and contemporaneous controls receiving institutional standard of care demonstrate the effectiveness of remestemcel-L in this patient population, with particular efficacy and survival benefit in patients with the most severe forms of aGVHD. These conclusions are supported by prior results from an Expanded Access Program in 241 children where remestemcel-L was used as salvage therapy after failure of steroids and other agents."

So i guess they show significant results, they just haven't disclosed the statistics. I've gone through all of their presentations and announcements and scientific ariticles and find nothing, so they've clearly decided to hold their hand close to their chest.